Patient-Reported Outcomes for LEMborexant Treatment in Chinese Patients with Insomnia (PROEM): A Multicenter, Prospective, Real-World Observational Study
Shuqiong Zheng, Xueli Li, Weiying Jian, Yamei Tang, Yongqiang Lin, Fujun Jia, Bin Zhang · 2026
Read Patient-Reported Outcomes for LEMborexant Treatment in Chinese Patients with Insomnia (PROEM): A Multicenter, Prospective, Real-World Observational Study by Shuqiong Zheng, Xueli Li, Weiying Jian, Yamei Tang, Yongqiang Lin, Fujun Jia, Bin Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13222614.txt.
Description
Shuqiong Zheng and co-authors report real-world outcomes for lemborexant, a sleep drug, in Chinese patients with insomnia, in a 2026 multicenter prospective study. Two hundred five adults with at least moderate insomnia scores were treated for twelve weeks across several centers. Remission after four weeks was the primary endpoint, with side effects tracked throughout.
About thirty percent reached remission at four weeks, and fifty-five percent met the responder bar. Insomnia scores began falling within the first week and kept improving, with mood and anxiety symptoms easing too. One fifth of patients reported a mild or moderate side effect, led by sleepiness, dizziness, and nightmares, and none were serious. Severe baseline insomnia predicted bigger gains but lower remission odds.
Catalog record
| CREATOR | Shuqiong Zheng, Xueli Li, Weiying Jian, Yamei Tang, Yongqiang Lin, Fujun Jia, Bin Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |